论文部分内容阅读
目的:评价特比萘芬连续疗法治疗糖尿病患者甲真菌病的有效性、安全性、耐受性和对患者血糖水平的影响。方法:90例糖尿病甲真菌病患者口服特比萘芬250mg,每日1次,指甲癣患者连续口服12周,趾甲癣患者连续口服16周;停药第24周观察最终疗效和血糖水平。结果:在第36周时,指甲真菌病的临床治愈率84.8%,有效率90.9%,真菌学治愈率93.9%;第40周时,趾甲真菌病的临床治愈率78.9%,有效率87.7%,真菌学治愈率89.5%;治疗前后空腹血糖和糖化血红蛋白水平无显著性差异。结论:特比萘芬治疗糖尿病患者甲真菌病有效、安全,耐受性良好;对患者血糖水平无明显影响。
OBJECTIVE: To evaluate the efficacy, safety, tolerability and efficacy of terbinafine in the treatment of onychomycosis in diabetic patients. Methods: Ninety patients with diabetic onychomycosis were treated with terbinafine 250 mg orally once daily for 12 weeks. Patients with onychomycosis were orally treated for 16 weeks continuously. The final therapeutic effect and blood glucose level were observed at 24 weeks after drug withdrawal. Results: At 36 weeks, the clinical cure rate of nail mycosis was 84.8%, the effective rate was 90.9% and the cure rate of mycology was 93.9%. The clinical cure rate of toenail fungal disease was 78.9% at the 40th week, the effective rate was 87.7% Mycology cure rate of 89.5%; before and after treatment, fasting blood glucose and glycosylated hemoglobin levels no significant difference. Conclusion: Terbinafine treatment of onychomycosis in diabetic patients effective, safe and well tolerated; no significant effect on blood glucose levels in patients.